Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Abbvie Inc (ABBV)

Abbvie Inc (ABBV)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 190,377,888
  • Shares Outstanding, K 1,767,176
  • Annual Sales, $ 45,804 M
  • Annual Income, $ 4,616 M
  • 60-Month Beta 0.82
  • Price/Sales 4.17
  • Price/Cash Flow 8.13
  • Price/Book 15.66
Trade ABBV with:

Options Overview

Details
  • Implied Volatility 23.77%
  • Historical Volatility 29.66%
  • IV Percentile 45%
  • IV Rank 17.03%
  • IV High 138.15% on 12/10/20
  • IV Low 0.29% on 12/16/20
  • Put/Call Vol Ratio 0.83
  • Today's Volume 37,569
  • Volume Avg (30-Day) 41,761
  • Put/Call OI Ratio 0.61
  • Today's Open Interest 487,468
  • Open Int (30-Day) 396,389

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/21
See More
  • Average Estimate 3.08
  • Number of Estimates 7
  • High Estimate 3.27
  • Low Estimate 2.25
  • Prior Year 2.83
  • Growth Rate Est. (year over year) +8.83%

Price Performance

See More
Period Period Low Period High Performance
1-Month
106.03 +1.60%
on 09/15/21
121.53 -11.36%
on 09/01/21
-11.93 (-9.97%)
since 08/17/21
3-Month
106.03 +1.60%
on 09/15/21
121.53 -11.36%
on 09/01/21
-7.17 (-6.24%)
since 06/17/21
52-Week
79.11 +36.18%
on 10/29/20
121.53 -11.36%
on 09/01/21
+18.10 (+20.19%)
since 09/17/20

Most Recent Stories

More News
AbbVie (ABBV) Files for Rinvoq in Ulcerative Colitis in US & EU

AbbVie (ABBV) files regulatory applications to the FDA and the EMA, seeking approval for a new indication of Rinvoq - active ulcerative colitis.

PFE : 43.89 (-1.30%)
LLY : 230.10 (-0.41%)
INCY : 75.99 (+1.27%)
ABBV : 107.73 (-0.32%)
Pharma Stock Roundup: ABBV's Deal With RGNX, LLY COVID Drug's Government Order Win

AbbVie (ABBV) buys rights to Regenexbio's gene therapy candidate for chronic retinal diseases. Lilly (LLY) will supply additional doses of its COVID-19 antibody medicine to the U.S. government.

MRK : 71.68 (-0.40%)
LLY : 230.10 (-0.41%)
ABBV : 107.73 (-0.32%)
TBPH : 7.11 (+3.64%)
AERI : 12.94 (+4.86%)
RGNX : 45.04 (+0.92%)
Lymphoproliferative Disorder Treatment Market Emerging Trends, Market Research, And Comprehensive Insights 2028

Research Nester released a report titled "" which delivers detailed overview of the global lymphoproliferative disorder treatment market in terms of market segmentation by route of administration, drug...

ATRA : 16.08 (+1.32%)
NOVN : 8.56 (+1.30%)
MRK : 71.68 (-0.40%)
BMY : 61.31 (+0.13%)
ABBV : 107.73 (-0.32%)
GILD : 71.61 (+0.39%)
AZN.LN : 8,063.001 (-0.96%)
PFE : 43.89 (-1.30%)
AbbVie Submits Regulatory Applications to FDA and EMA for Upadacitinib (RINVOQ®) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis

/PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that it has submitted applications seeking approval for upadacitinib (15 mg and 30 mg (maintenance dose) and 45 mg (induction dose)) for the treatment...

ABBV : 107.73 (-0.32%)
Ophthalmology Equipment Market Expected Growth and its Factors, CAGR, Industry Size, Business Prospects and Forecast 2029

Research Nester published a report titled ": Global Demand Analysis & Opportunity Outlook 2029" which delivers detailed overview of the global ophthalmology equipment market in terms of market segmentation...

NVS : 83.48 (-1.07%)
CZMWY : 232.5000 (-0.64%)
HOCPY : 169.2000 (-2.74%)
PFE : 43.89 (-1.30%)
ABBV : 107.73 (-0.32%)
SNPHY : 15.2700 (-1.29%)
TOPCF : 18.2350 (+1.35%)
ObsEva (OBSV) Files NDA for Linzagolix to Treat Uterine Fibroids

ObsEva (OBSV) submits an NDA to the FDA for linzagolix as a potential treatment for uterine fibroids.

REGN : 651.88 (-0.20%)
VRTX : 188.30 (+0.64%)
ABBV : 107.73 (-0.32%)
OBSV : 3.34 (+8.44%)
AbbVie (ABBV) Dips More Than Broader Markets: What You Should Know

AbbVie (ABBV) closed the most recent trading day at $106.48, moving -0.93% from the previous trading session.

ABBV : 107.73 (-0.32%)
REGENXBIO (RGNX) Stock Up on Collaboration Deal With AbbVie

REGENXBIO (RGNX) enters into a strategic partnership with AbbVie to co-develop and commercialize RGX-314, a potential gene therapy for retinal indications. Resultantly, REGENXBIO's share price surges.

REGN : 651.88 (-0.20%)
BAYRY : 13.2900 (-1.41%)
ABBV : 107.73 (-0.32%)
RGNX : 45.04 (+0.92%)
DiaMedica (DMAC) Initiates Pivotal Ischemic Stroke Study

DiaMedica (DMAC) is developing its recombinant KLK1 protein candidate, DM199 for treating patients who suffered an acute ischemic stroke in the last 24 hours as well as for reducing the risk of recurrent...

BIIB : 300.19 (+0.17%)
PFE : 43.89 (-1.30%)
ABBV : 107.73 (-0.32%)
DMAC : 4.18 (+3.21%)
AbbVie (ABBV) to Co-Develop Regenxbio Eye Disease Gene Therapy

AbbVie (ABBV) is set to co-develop Regenexbio's investigational gene therapy for chronic retinal diseases like wet age-related macular degeneration.

ABBV : 107.73 (-0.32%)
RGNX : 45.04 (+0.92%)
GMAB : 43.12 (+1.99%)
IMAB : 75.85 (+11.31%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakening short term outlook on maintaining the current direction.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

AbbVie is a global, research-based biopharmaceutical company. AbbVie combines the focus and passion of a leading-edge biotech with the expertise and structure of a long-established pharmaceutical leader. The company's mission is to use its expertise, dedicated people and unique approach to innovation...

See More

Key Turning Points

3rd Resistance Point 109.43
2nd Resistance Point 108.84
1st Resistance Point 108.29
Last Price 107.73
1st Support Level 107.14
2nd Support Level 106.55
3rd Support Level 105.99

See More

52-Week High 121.53
Last Price 107.73
Fibonacci 61.8% 105.33
Fibonacci 50% 100.32
Fibonacci 38.2% 95.31
52-Week Low 79.11

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar